论文部分内容阅读
伤寒沙门菌Vi荚膜多糖抗原(VI-CPS)是对抗伤寒热的有效疫苗。因评估VI-CPS疫苗对伤寒热的保护功效没有可用的动物模型,所以血清杀菌试验(SBA)是评估其效力所推荐的“金标准”。利用已优化的Gotschlich法从伤寒沙门菌Ty6S(CSBPI-B191)中提取VI-CPS。用纯化的VI-CPS(50μg),肌内注射3组兔子,每组5只,第2组在第15天再注射1剂50μgVI-CPS加强剂量,第3组在第15天和30天分别再注射2剂加强剂量。利用SBA对各组在第0、15、30和45天获得的血清进行了测试。
Salmonella typhi Vi capsular polysaccharide antigen (VI-CPS) is an effective vaccine against typhoid fever. Therefore, the serum bactericidal test (SBA) is the recommended “gold standard” for assessing its efficacy, as there is no animal model available to assess the efficacy of the VI-CPS vaccine in protecting against typhoid fever. VI-CPS was extracted from S. typhi Ty6S (CSBPI-B191) using the optimized Gotschlich method. Three rabbits in each group were intramuscularly injected with purified VI-CPS (50 μg), with 5 rabbits in each group. Group 2 received a single bolus of 50 μg of the booster dose of VI-CPS on day 15 and group 3 on days 15 and 30, respectively Re-injection of two doses to strengthen. Sera obtained on days 0, 15, 30 and 45 of each group were tested using SBA.